CANY
AXSM icon

Caxton Associates (New York)’s Axsome Therapeutics AXSM Stock Holding History

Caxton Associates (New York)’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,478
Closed -$558K – 459
2020
Q1 		$558K Buy
+9,478
New +$772K 0.1% 134

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caxton Associates (New York)'s AXSM Position: Q2 2020 in Review

Caxton Associates (New York) sold out of Axsome Therapeutics (AXSM) in Q2 2020, closing a stake of 9,478 shares — an estimated $558K sold.

Caxton Associates (New York) first reported a position in AXSM in Q1 2020 and held it in 1 quarter. The position peaked at $558K in Q1 2020. 190 funds tracked by Wall St. Rank hold AXSM as of Q2 2020.

  • Caxton Associates (New York) reported no remaining Axsome Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 9,478 Axsome Therapeutics shares in Q2 2020, an estimated $558K.
  • Caxton Associates (New York) first reported a position in Axsome Therapeutics in Q1 2020 and held it in 1 quarter.
  • Caxton Associates (New York)'s Axsome Therapeutics position peaked at $558K in Q1 2020.
  • 190 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.